Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 4 (2007), Issue 3 (March)

1. Skin and stomach graft versus host disease after syngeneic BMT in CML: A case report.
   Leuk Res. [Abstract] [Full-text]
2. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets.
   J Clin Invest, 117(3): 823-34. [Abstract] [Full-text]
3. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
   Clin Cancer Res, 13(5): 1367-73. [Abstract] [Full-text]
4. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
   Pathol Res Pract, 203(3): 127-34. [Abstract] [Full-text]
5. The 2.7 A crystal structure of the autoinhibited human c-Fms kinase domain.
   J Mol Biol, 367(3): 839-47. [Abstract] [Full-text]
6. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
   Blood, 109(6): 2303-9. [Abstract] [Full-text]
7. The Src tyrosine kinase Hck is required for Tel-Abl- but not for Tel-Jak2-induced cell transformation.
   Oncogene, 26(11): 1577-85. [Abstract] [Full-text]
8. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.
   EMBO J, 26(5): 1456-66. [Abstract] [Full-text]
9. Kinase Mutations and Imatinib Mesylate Response for 64 Taiwanese with Advanced GIST: Preliminary Experience from Chang Gung Memorial Hospital.
   Ann Surg Oncol, 14(3): 1123-8. [Abstract] [Full-text]
10. Autologous stem cells collected after debulking by high dose chemotherapy in late phase chronic myeloid leukemia may improve Imatinib efficacy.
    Transfus Apher Sci, 36(1): 91-4. [Abstract] [Full-text]
11. Multiple paths to a drug resistance phenotype: Mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs.
    Drug Resist Updat. [Abstract] [Full-text]
12. Late-appearing pseudocentric fission event during chronic myeloid leukemia progression.
    Cancer Genet Cytogenet, 174(1): 61-7. [Abstract] [Full-text]
13. An inv(16) in Ph-negative cells of a chronic myelogenous leukemia patient after imatinib treatment.
    Cancer Genet Cytogenet, 174(1): 54-6. [Abstract] [Full-text]
14. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.
    Neuro-oncol, 9(2): 145-60. [Abstract] [Full-text]
15. c-Src Binds to the Cancer Drug Imatinib with an Inactive Abl/c-Kit Conformation and a Distributed Thermodynamic Penalty.
    Structure, 15(3): 299-311. [Abstract] [Full-text]
16. Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia.
    Expert Opin Emerg Drugs, 12(1): 165-79. [Abstract] [Full-text]
17. Emerging drugs for the treatment of soft tissue sarcomas.
    Expert Opin Emerg Drugs, 12(1): 139-53. [Abstract] [Full-text]
18. Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country.
    Cancer, 109(6): 1138-45. [Abstract] [Full-text]
19. CD117 (c-kit) expression in human hepatocellular carcinoma.
    Clin Oncol (R Coll Radiol), 19(3): 204-8. [Abstract] [Full-text]
20. Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas.
    Proc Natl Acad Sci U S A, 104(9): 3414-9. [Abstract] [Full-text]
21. Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.
    Proc Natl Acad Sci U S A, 104(11): 4594-9. [Abstract] [Full-text]
22. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
    Cancer Res, 67(6): 2685-92. [Abstract] [Full-text]
23. From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way.
    Clin Cancer Res, 13(6): 1638-42. [Abstract] [Full-text]
24. Resistance to c-KIT kinase inhibitors conferred by V654A mutation.
    Mol Cancer Ther, 6(3): 1159-66. [Abstract] [Full-text]
25. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases.
    J Pharmacol Exp Ther, 321(1): 35-44. [Abstract] [Full-text]
26. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
    J Clin Oncol, 25(9): 1107-13. [Abstract] [Full-text]
27. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis.
    Am J Clin Pathol, 127(4): 642-50. [Abstract] [Full-text]
28. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
    J Pharmacol Exp Ther, 321(1): 288-97. [Abstract] [Full-text]
29. The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate.
    Cancer Chemother Pharmacol, 59(6): 855-60. [Abstract] [Full-text]
30. Bone marrow aplasia--a rare complication of imatinib therapy in CML patients.
    Am J Hematol, 82(4): 314-6. [Abstract] [Full-text]
31. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.
    Lab Invest, 87(4): 365-71. [Abstract] [Full-text]
32. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk.
    J Perinatol, 27(4): 241-3. [Abstract] [Full-text]
33. Rectal GIST presenting as a submucosal calculus.
    Dig Dis Sci, 52(4): 1047-9. [Abstract] [Full-text]
34. Optimizing therapy of chronic myeloid leukemia.
    Exp Hematol, 35(4): 144-54. [Abstract] [Full-text]
35. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
    Gynecol Oncol, 105(1): 122-31. [Abstract] [Full-text]
36. Molecular targeted therapy for carcinoid and islet-cell carcinoma.
    Best Pract Res Clin Endocrinol Metab, 21(1): 163-72. [Abstract] [Full-text]
37. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.
    Urology, 69(3): 526-31. [Abstract] [Full-text]
38. Microfluidic deletion/insertion analysis for rapid screening of KIT and PDGFRA mutations in CD117-positive gastrointestinal stromal tumors: diagnostic applications and report of a new KIT mutation.
    J Mol Diagn, 9(2): 151-7. [Abstract] [Full-text]
39. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate.
    J Cutan Pathol, 34(4): 324-9. [Abstract] [Full-text]
40. Resistance to imatinib mesylate in chronic myeloid leukaemia.
    Cancer Lett, 249(2): 121-32. [Abstract] [Full-text]
41. Endothelial cell KIT expression in human tumours.
    J Pathol, 211(4): 481-8. [Abstract] [Full-text]
42. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
    Biochem Biophys Res Commun, 356(2): 323-8. [Abstract] [Full-text]
43. Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia.
    FEBS Lett, 581(7): 1329-34. [Abstract] [Full-text]
44. Identification of imatinib mesylate degradation products obtained under stress conditions.
    J Pharm Biomed Anal, 43(5): 1682-91. [Abstract] [Full-text]
45. Vascular endothelial growth factor receptor-3 activity is modulated by its association with caveolin-1 on endothelial membrane.
    Biochemistry, 46(13): 3998-4005. [Abstract] [Full-text]
46. Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns.
    Cancer, 109(7): 1365-75. [Abstract] [Full-text]
47. Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro.
    Cancer Immunol Immunother, 56(6): 849-61. [Abstract] [Full-text]
48. Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment.
    Endocr Relat Cancer, 14(1): 61-72. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.